Fig 1: CRISPR-Engineered Hyperstabilized cyclin D3 Mutant Mice Increase DZ Expansion(A) Generation of Ccnd3T283A/+ mice was achieved by microinjection of Cas9 mRNA, Ccnd3 sgRNA, and Ccnd3T283A ssODN into zygotes from superovulated C57BL/6 female mice.(B) DNA sequencing chromatogram shows the point mutation and resulting amino acid change in a heterozygous animal for Ccnd3T283A/+.(C) Assessment of cyclin D3 protein levels in Ccnd3T283A/+ mice. The B splenocytes from Ccnd3T283A/+ or Ccnd3+/+ mice were cultured in the presence of indicated stimulants for 16 h, and cell lysates were probed for cyclin D3 (and ß-actin as a loading control). Data are representative of two independent experiments.(D) Irradiated (10 Gy) C57BL/6 recipient mice were reconstituted with bone marrow from Ccnd3+/+ or Ccnd3T283A/+ mice. After 6 weeks, mice were immunized with SRBCs and analyzed 10 days later. Single cells were gated on B splenocytes (B220+) to determine GC B cell frequency based on GL7+FAS+ expression.(E) Quantification of (D) GC B cells in Ccnd3T283A/+ mice compared with Ccnd3+/+ control mice (n = 8).(F) Zonal distribution of GC B cells (shown in D) based on relative expression of CXCR4hiCD86lo (DZ) and CXCR4loCD86hi (LZ).(G) Quantification of (F) GC B cells respective DZ/LZ ratio (n = 8).(H) Antibody titers of SRBC-specific IgM or IgG1 in sera from Ccnd3+/+ or Ccnd3T283A/+ mice (n = 8).(I) Immunofluorescence of GC reaction in Ccnd3T283A/+ and Ccnd3+/+ mice. Mice were immunized with NP-CGG and analyzed on day 14. Splenic follicles with B cells (B220+) and GC B cells (PNA+) are shown. CD35 expression on follicular dendritic cells depicts the LZ of the GC. Scale bar, 100 µm. Data are representative of three independent experiments.
Supplier Page from Thermo Fisher Scientific for CD21/CD35 Antibody FITC